Literature DB >> 24780929

Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Xuesong Wu1, Brian C Schulte1, Youwen Zhou2, Dipica Haribhai3, Alexander C Mackinnon4, Jose A Plaza4, Calvin B Williams3, Sam T Hwang5.   

Abstract

Macrophages have key roles in tumor development and invasion in several human cancers, but little is known about their pathogenic role in cutaneous T-cell lymphoma (CTCL). Herein, we used PCR arrays to profile the expression of inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL. Compared with normal controls, MF skin displayed increased mRNA levels of macrophage-related cytokines. Moreover, we detected CD163, a reliable marker of tumor-associated macrophages, in the tumor microenvironment of MF biopsies. To demonstrate that macrophages had a role in CTCL tumorigenesis, we xenografted human CTCL tumor cells in immunocompromised mice and compared tumor development using clodronate-containing liposomes to deplete macrophages in mice. Mice treated with clodronate-containing liposomes show markedly less tumor growth compared with mice treated with phosphate-buffered saline-containing liposomes (P<0.001). We also noted a strong correlation between macrophage depletion and decreased expression of vascular marker, CD31, and lymphatic marker, podoplanin, suggesting a role for macrophages in angiogenesis. In vitro, clodronate-containing liposomes killed activated murine M2 macrophages, but not Hut78 cells, demonstrating selective ability to induce apoptosis in macrophages. Our data indicate that macrophages have a critical role in the progression of Hut78 cell tumor formation in skin, thus providing a new therapeutic strategy for CTCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24780929     DOI: 10.1038/jid.2014.206

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  27 in total

1.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  Molecular markers of early-stage mycosis fungoides.

Authors:  Yaohua Zhang; Yang Wang; Richard Yu; Yuanshen Huang; Mingwan Su; Cheng Xiao; Magdalena Martinka; Jan P Dutz; Xuejun Zhang; Zhizhong Zheng; Youwen Zhou
Journal:  J Invest Dermatol       Date:  2012-03-01       Impact factor: 8.551

Review 4.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

5.  Benign and malignant lymphocytic skin infiltrates: immunological patterns recognized by immunohistochemical staining with monoclonal antibodies.

Authors:  E Ralfkiaer; K Hou-Jensen; D Y Mason; H Stein; G L Wantzin; K Thomsen
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

6.  Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3.

Authors:  Yukio Fujiwara; Yoshihiro Komohara; Rino Kudo; Keiichiro Tsurushima; Koji Ohnishi; Tsuyoshi Ikeda; Motohiro Takeya
Journal:  Oncol Rep       Date:  2011-09-12       Impact factor: 3.906

7.  Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells.

Authors:  Adrien Kissenpfennig; Sandrine Henri; Bertrand Dubois; Corinne Laplace-Builhé; Pierre Perrin; Nikolaus Romani; Christoph H Tripp; Patrice Douillard; Lee Leserman; Dominique Kaiserlian; Sem Saeland; Jean Davoust; Bernard Malissen
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 8.  Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization.

Authors:  Michael Girardi; Carole Berger; Douglas Hanlon; Richard L Edelson
Journal:  Technol Cancer Res Treat       Date:  2002-02

9.  Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.

Authors:  Makoto Sugaya; Tomomitsu Miyagaki; Hanako Ohmatsu; Hiraku Suga; Hiromichi Kai; Masahiro Kamata; Hideki Fujita; Yoshihide Asano; Yayoi Tada; Takafumi Kadono; Hitoshi Okochi; Shinichi Sato
Journal:  J Dermatol Sci       Date:  2012-07-27       Impact factor: 4.563

10.  Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Authors:  Jamie Honeychurch; Monique H M Melis; Simon J Dovedi; Lijun Mu; Timothy M Illidge
Journal:  Leuk Lymphoma       Date:  2013-02-18
View more
  37 in total

1.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.

Authors:  Alyxzandria M Gaydosik; Dawn S Queen; Megan H Trager; Oleg E Akilov; Larisa J Geskin; Patrizia Fuschiotti
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

4.  Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice.

Authors:  Xuesong Wu; Timothy W Wang; George M Lessmann; Jamal Saleh; Xiping Liu; Christopher R Chitambar; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-11-05       Impact factor: 8.551

5.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

Review 6.  Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.

Authors:  Cristina Cristofoletti; Antonella Bresin; Martina Fioretti; Giandomenico Russo; Maria Grazia Narducci
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 7.  Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

Review 8.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

9.  The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.

Authors:  Oleg Kruglov; Xuesong Wu; Sam T Hwang; Oleg E Akilov
Journal:  Blood Adv       Date:  2020-10-13

Review 10.  Macrophages in dermatology: pathogenic roles and targeted therapeutics.

Authors:  Drew Kuraitis; Nadia Rosenthal; Erin Boh; Elizabeth McBurney
Journal:  Arch Dermatol Res       Date:  2021-02-28       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.